QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Disagreement Between Member States During MRP or DCP

Test your understanding of the concepts covered by What Happens When Member States Disagree During an MRP or DCP?.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the primary objective of the coordination-group stage under Article 29?

To determine which national authority made the original error To reach agreement among the Member States within the applicable framework To replace the applicant's scientific assessment To establish automatically that the medicine has an unfavourable benefit-risk balance

Question 2 of 10 What opportunity must be given to the applicant during the coordination-group stage?

The opportunity to make its views known orally or in writing The opportunity to appoint the RMS The opportunity to determine the applicable legal basis The opportunity to prevent any referral regardless of the evidence

Question 3 of 10 What should happen to the scientific question when a disagreement escalates to the Union level?

It should be broadened to include every unresolved product issue It should be clearly defined, separating the evidence, CMS objection, applicant response and unresolved point It should be replaced by the question of which Member State was correct It should be reduced to a purely legal question

Question 4 of 10 If the Member States reach agreement within the coordination-group stage, what outcome is described in the article?

The matter must still automatically proceed to CHMP The RMS records the agreement, closes the procedure and informs the applicant The applicant becomes responsible for issuing national decisions The CMS objection is converted into a confirmed safety finding

Question 5 of 10 Which situation most clearly meets the legal trigger for an Article 29 disagreement?

A CMS requests clarification of an assessment conclusion A CMS proposes alternative wording for the package leaflet A CMS cannot approve the relevant regulatory position because it considers there is a potential serious risk to public health The RMS and CMS have different preferences regarding the format of the assessment report

Question 6 of 10 What should a CMS provide when formally maintaining a qualifying Article 29 position?

A general statement that the product is unsafe A detailed exposition of the reasons for its position A request for the applicant to withdraw the application A final Union-level scientific opinion

Question 7 of 10 Which applicant response would most appropriately support resolution of an Article 29 disagreement?

A statement that the CMS should defer to the RMS A response addressing the evidence, the disputed risk, proposed product information and possible risk-management measures A decision to communicate only with the national authority raising the concern A general assurance that no further assessment is necessary

Question 8 of 10 For a human medicines MRP or DCP disagreement, which body is the relevant coordination group described in the article?

CHMP CMDh PRAC The European Commission only

Question 9 of 10 Which statement best distinguishes the Article 29 stage from the subsequent Union-level procedure?

Article 29 concerns the MRP/DCP disagreement, while Articles 32 to 34 govern the subsequent Union-level procedure Article 29 and Articles 32 to 34 are interchangeable names for the same stage Article 29 applies only after a Union-level committee has issued an opinion Articles 32 to 34 apply only to routine package-leaflet wording questions

Question 10 of 10 Why is it inaccurate to describe escalation under Article 29 simply as an appeal against the RMS?

Because the applicant has no role after escalation Because escalation is a statutory transition from the MRP/DCP coordination mechanism to a Union-level procedure Because the RMS is not involved in any part of an MRP or DCP Because Article 29 applies only to administrative matters

QPPV.com

Knowledge Assessment: Disagreement Between Member States During MRP or DCP

Cookie Settings